Slide 1: Annual Shareholders Meeting October 2021
Annual Shareholders Meeting October 2021
Slide 2: Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a
Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to sub
Slide 3: Company Overview and Chair's Address
Company Overview and Chair’s Address 3
Slide 4: Co-Founders
Panapa Ehau Manu Caddie Ngāti Uepohatu, Ngāti Ngāti Pūkenga, Ngāti Hauā Porou Kaihautu - Innovation and Director, Co-Founder Regulation, Co-Founder 4
Slide 5: Our vision at Rua Bioscience
Our vision at Rua Bioscience is simple – to create cannabinoid- derived medicines that change people’s lives; from right here in Te Tairāwhiti.
Slide 6: Our Strategy – Focus and Objectives
Te Rautaki o Rua Our Strategy – Focus and Objectives Creating Unique Product and • Create unique, sustainable and protected IP, cultivation techniques Plant IP • Develop commercially viable varieties of cultivars • Use research partners to develop IP • Create new, protected product formulations Deve
Slide 7: Board of Directors
Te Paori Ringatohu Board of Directors Independent Director, Director Independent Independent Chairman Co-Founder Ringatohu Director Director Heamana Kaiwhakaū / Whakatū Pū Ringatohu Ringatohu Whakatū Pū Ringatohu Wehe Kē Whakatū Pū Whakatū Pū Wehe Kē Ngāti Pehe Kē Pehe Kē Uepohatu, Appointed Appoint
Slide 8: Achievements at a Glance
Māwhiti mai ki ngā Whakatutukitanga Achievements at a Glance Successfully Built new Signed Received Exported first listed on NZX. facilities in exclusive New commercial sample Ruatorea and Zealand licence to grow medicinal Tūranga supplier sales and supply cannabis /Gisborne. agreement cannabis- flo
Slide 9: Achievements at a Glance
Māwhiti mai ki ngā Whakatutukitanga Achievements at a Glance Attracted key Announced Developed the Received Received GMP staff critical to hyperspectral Rua commercial Certification of the imaging Sustainability licence to grow our Gisborne commercialisat project with Framework. and supply manufactu
Slide 10: Our Shareholders
GEOGRAPHICAL SPREAD OF OUR SHAREHOLDING Te Tairāwhiti Nga Kaipupuri Hea AS AT 30 JUNE 2021 Our Shareholders Auckland l 37.23% of our Shareholders l 20.58% of our l Hold 19.47% of shareholders Rua’s shares As at 30 June 2021: l Hold 17.37% of Bay of Plenty Rua’s shares • 2,901 shareholders l 6.45% of
Slide 11: Our Shareholders – Top Holders
Nga Kaipupuri Hea Our Shareholders Top 10 Holders 1. Fang Group Investment Ltd 2. Hikurangi Bioactives Ltd Partnership 3. Tailorspace Capital Ltd 4. NZ Depository Nominee Ltd 5. Andrew Charles Williams 6. FNZ Custodians Ltd 7. Ridings Brothers Ltd 8. Custodial Services Ltd 9. Wakaroma A/C 10. Forsyt
Slide 12: Chief Executive Officer's Presentation
Chief Executive Officer’s Presentation 12
Slide 13: Creating Value – GMP Certification
Hanga Wāriu Creating Value Good Manufacturing Practice (GMP) Certification Globally recognised minimum standards for the manufacture of medicines. Prerequisite for commercial production. Key step on the path to revenue. Rua began audit in November 2020 and achieved GMP certification of the Gisborne
Slide 14: Progress on Cultivation Optimization and Capacity
Hanga Wāriu Creating Value Progress on Cultivation Optimization and Capacity Well advanced in establishing our commercial cultivars. Rua has signed three supply agreements with grower partners and an R&D supply agreement. Trial started with the East Coast Cannabis Company on site in October 2021. Su
Slide 15: Creating Value – Research and Development
Hanga Wāriu Creating Value Research and Development Rua announced a ground-breaking, two- year research programme to investigate the application of hyperspectral technology to the cultivation and assessment of medicinal cannabis, paving the way for Rua to enter New Zealand's booming agritech sector.
Slide 16: Senior Management
Ngā Pou Matua Senior Management Chief Innovation and Chief Financial Chief Chief Research Chief Executive Regulation, Officer Operations Officer Commercial Officer Co-Founder Āpiha Officer Āpiha Officer Kaiwhakahāere Kaiwhakaū / Kaiwhakahāere Āpiha Kairangahau Āpiha Kaihoko Matua Kaihautu Pūtea Kait
Slide 17: Recruiting for the Future
Ngā Whakaurunga Āmua Recruiting for the Future Len Walker Ngāti Porou, Aitanga-a-Hauiti, Te Whānau-a-Apanui Kaiwhakahāere hangahanga Cultivation Manager MBA Len returns home having carved out an impressive management career in the Dairy industry that takes in Tui Co-operative Dairy Company, the NZ D
Slide 18: New Zealand Market Forecast
Te Matapae o te Mākete o Aotearoa CBD PRODUCTS SUPPLIED PER ANNUM TO THE NZ 31,000 MARKET New Zealand Market Forecast New Zealand is growing rapidly off a small base. 21,964 The number of packs of CBD products supplied in New Zealand in the year to 30 June 2021 was over 31,000. This compares to just
Slide 19: German Market Opportunities
MARKET SHARE OF Ngā mea Angitū o te Mākete ki CANNABIS DRUGS IN GERMANY Tiāmana German Market Opportunities 50% Germany is currently the largest single market 40% for GMP (pharmaceutical) grade cannabis globally. 30% Public health insurance coverage of prescriptions reached €90M in the first half of
Slide 20: Global Market Opportunities
Ngā mea Angitū o te Mākete o te Ao CANNABIS LEGALISATION TO MARCH 2021 Available via import* Global Market Opportunities Production legalised Treatment legalised Medical and Recreational adult use legalised† * In exceptional circumstances † Includes countries with potential upcoming legalisation or
Slide 21: Guidance on Timing
Ārahitanga Whakahāere Guidance on Timing Q1 Late Q1 Early Q2 Q4 Dec 2022 2022 2022 2023 New Markets First First Self-Sustaining End of Cash Domestic Revenue Export Revenue Revenue Runway Expanded export Product available Product made With Based on our strategy for New Zealand available to German app
Slide 22: Opportunities and Challenges
Ngā mea Angitū me ngā Wero Opportunities and Challenges Opportunities • Markets opening around the world • Growing body of clinical evidence Challenges • Decades of stigma • Meeting Minimum Quality Standards • Expansion of foreign markets 22
Slide 23: Towards Sustainability
Whai Hua mo Apōpō Towards Sustainability Hamish Harris Ngāti Porou, Nga Puhi Plant Health Specialist 23
Slide 24: Community Engagement
Whakapā atu ki te Iwi Whānui Community Engagement 24
Slide 25: Annual Results
Annual Results 25 RUA
Slide 26: Results at a Glance
Māwhiti mai ki ngā Hua Nui Results at a Glance Cash and Funds Other Investment Investment Loss after Investments Raised Income in R&D in Property, Tax Plant and $16.4M $20M $451K $1.9M Equipment -$4.42M $6.17M 26
Slide 27: Results at a Glance – Profit and Loss
Māwhiti mai ki ngā Hua Nui Results at a Glance – Profit and Loss Loss before tax $6.17M Investment in R&D $1.90M Other income $451K Income Tax Credit $1.75M Loss after Loss after tax $4.42M Tax -$4.42M 27
Slide 28: Results at a Glance – Balance Sheet
Māwhiti mai ki ngā Hua Nui Results at a Glance – Balance Sheet Cash & Investments $16.4M Investment in property, plant and equipment $6.17M Total assets $30.8M Total liabilities $2M Net assets $28.8M Net Assets $28.8M 28
Slide 29: Results at a Glance - Cashflow
Māwhiti mai ki ngā Hua Nui Results at a Glance - Cashflow Net cash outflow from operating activities $4.48M Net cash outflow from investing activities $14.43M Net cash inflow from financing activities $18.3M Net Cash Inflow $18.3M 29
Slide 30: Nga mihi, e noho rā
Nga mihi, e noho rā